Safety Alerts Saves Lives
Safety Alerts  
Home Privacy About Us Contact Us Change Preferences
spacer.gif (43 bytes)
March 26,  2002

Animal Model Study Demonstrated Reovirus as an Effective Treatment for Breast Cancer

(SafetyAlerts) - Oncolytics Biotech Inc. ('Oncolytics') announces the publication of a research paper entitled "Reovirus Oncolysis of Human Breast Cancer" by Norman et. al (Human Gene Therapy, Vol. 13, March 20, 2002), which examined the use of the reovirus as a treatment for breast cancer in animal models. Oncolytics is currently developing a formulation of the human reovirus REOLYSIN(R), as a potential therapeutic against Ras-activated cancers.

The study examined two animal models of breast cancer to demonstrate the effectiveness of the reovirus in causing tumour regression. In the first model, human breast cancer cells were implanted over the mammary fat pad of the SCID/NOD mice. After a tumour had been established, a single injection of the reovirus caused a continuous regression of the tumour during a thirty-day observation period. In the second animal model, independent tumours were established on both flanks of the mice (bilateral model). After the tumours had been established, a single injection of the reovirus into only one tumour resulted in complete regression of both the injected and non-injected tumours over thirty-two days.

The research group also examined the ability of the reovirus to infect and to kill breast cancer cell lines. Widespread cell killing was seen in all five established breast cancer cell lines and in one surgical specimen. No cell killing was observed in two cell lines established from normal breast tissue.

"The reovirus clearly demonstrated effectiveness in this study," said Dr. Matt Coffey, Vice President, Product Development and one of the co-authors of the study. "In the bilateral animal model, the reovirus levels were approximately the same in the injected and non-injected tumours over the last half of the study, and reovirus was detectable in the blood throughout the investigation. These results support our plans to start human trials in which REOLYSIN(R) will be administered systemically."

Breast cancer is the most common cancer in women, accounting for about 31% of new cases. The American Cancer Society estimates that there will be 203,500 new cases of breast cancer diagnosed and 39,600 deaths in 2002 in the United States. While the five-year relative survival rate for local breast cancer is 96%, the survival rate for metastatic disease is only 21%.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of the human reovirus (REOLYSIN(R)), as a potential cancer therapeutic. Oncolytics' researchers have demonstrated that the reovirus is able to selectively kill human cancer cells in vitro that are derived from many types of cancer, including breast, prostate, pancreatic and brain tumours, and have also demonstrated successful cancer treatment results in a number of animal models. Phase I clinical trial results have indicated that there were no toxicology-related issues with the administration of the reovirus, and that the reovirus demonstrated activity in tumours injected with REOLYSIN(R). Oncolytics has filed a Clinical Trial Application (CTA) with Health Canada and with the FDA for a Phase I/II trial investigating the treatment of recurrent malignant glioma patients.

Source: PRNewswire

Selected Recent Recalls

Health Professional:

Did you know?
During 2000 there were over
1050 products recalled in the United
States for safety reasons!

How many did you hear about?

Sign-up for SafetyAlerts by Email -
The free internet newsletter that could
some day literally save your life - or
the life of someone you know.


The information contained herein has been obtained from sources that the Company believes to be reliable, however, the Company has not independently verified or confirmed the information and the recipient acknowledges that no representations or warranties are being made in connection with the use of the information.